Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | Correlation between Trop2 and pCR in patients with HER2-positive early breast cancer

Maria Gion • 2 Jun 2024
ASCO 2024
Breast Cancer Antibodies Carboplatin Docetaxel Pertuzumab Trastuzumab

Maria Gion, MD, Ramón y Cajal University Hospital, Madrid, Spain, discusses recent findings on the correlation between Trop2 expression and pathologic complete response (pCR) in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab. Patients with low Trop2 expression had the best pCR rates, whilst patients with high Trop2 expression had the worst pCR rate. This opens the way for future combinations of anti-Trop2 therapies with anti-HER2 therapies to circumvent this resistance mechanism. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consulting or Advisory Role – AstraZeneca; Gilead Sciences
Speakers’ Bureau – AstraZeneca; Gilead Sciences; Novartis; Pfizer
Travel, Accommodations, Expenses – AstraZeneca; Pfizer; Roche

More from Maria Gion

Insights into the future of AKT inhibitors combination with chemotherapies for aTNBC
0:45
Insights into the future of AKT inhibitors combination with chemotherapies for aTNBC
Maria Gion • 2 Jun 2024
PATHFINDER: ipatasertib with non-taxane chemotherapy in patients with aTNBC
1:20
PATHFINDER: ipatasertib with non-taxane chemotherapy in patients with aTNBC
Maria Gion • 2 Jun 2024

Related Videos

CRCI and compromised adjuvant chemotherapy delivery in cancer
5:16
CRCI and compromised adjuvant chemotherapy delivery in cancer
Filippos Koinis • 1 Jun 2026
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
1:20
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
Sarbajit Mukherjee • 1 Jun 2026
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
The content of VJOncology is intended for healthcare professionals